康躍科技(300391.SZ)正籌劃重大資產重組事項 擬收購湖北長江星醫藥不少於51%股權
格隆匯6月8日丨康躍科技(300391.SZ)公佈,公司正在籌劃重大資產重組事項,公司擬以現金方式收購湖北長江星醫藥股份有限公司不少於51%的股權。經初步測算,該事項構成重大資產重組。
湖北長江星醫藥股份有限公司主營業務:公司所屬行業為衞生材料及醫藥用品製造,構築了新型醫藥膠囊生產、醫藥物流網絡、中成藥新藥、中藥飲片及中藥原料藥生產為一體的醫藥產業鏈佈局。
此次交易尚處於初步籌劃階段,相關方案尚需進一步論證協商,並需按照法律、法規及公司章程的規定履行必要的決策和審批程序。此次交易相關事項尚存在重大不確定性,敬請廣大投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.